Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 245.03M shares rose 8.4% year over year, behind the +16.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 6.5% from the prior quarter. Over 3 fiscal years it compounded at +10.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +8.4% toward the trailing-twelve-month pace of +16.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
245.03M+6.5% QoQ
Last fiscal yearDec 2025
230.12M+14.9% YoY
LTMMar 2026
233.09M+16.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.4%——
1 year+14.9%——
3-year CAGR+10.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
230.12M USD
Year-over-year change
+14.9%
4-year CAGR
+8.8%

Weighted Avg Shares vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 weighted avg shares of 233.09M shares is the highest of the 4 companies compared; the peer median is 86.45M shares.
  • Its year-over-year change of +16.0% is the highest of 4, against a peer median of +7.2%.
  • Over three fiscal years its annual growth of +10.7% compares with a peer median of +15.6%.
LCTX Competitors Peer median
Weighted Avg Shares for LCTX and competitors
Company Period LTM YoY 3-year CAGR
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026233.09M +16.0%+10.7%
MESOMesoblast LimitedLTM Jun 2026129.46M +7.2%+15.6%
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
CELUCelularity Inc.LTM Dec 202524.87M +13.6%+22.3%
Peer median (excluding LCTX) 86.45M+7.2%+15.6%

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.9M14.7M8.95M9.5M14.56M
Cost of Revenue1.43M728K671K334K845K
Gross Profit2.47M13.98M8.27M9.17M13.71M
Gross Margin63.4%95.0%92.5%96.5%94.2%
Research & Development33.91M13.99M15.71M12.47M17.73M
Selling, General & Admin18.21M22.51M17.3M18.17M18.46M
Operating Expenses51.68M36.5M33.01M30.64M35.49M
Depreciation & Amortization873K727K692K609K699K
EBITDA(42.4M)(25.09M)(22.59M)(17.97M)(67.95M)
EBITDA Margin-1088.2%-170.6%-252.5%-189.2%-466.8%
Operating Income(49.21M)(22.52M)(24.73M)(21.48M)(21.78M)
Operating Margin-1263.1%-153.2%-276.5%-226.1%-149.6%
Interest Income2K829K1.63M1.72M1.69M
Interest Expense00000
Other Income / Expenses5.94M(3.29M)1.45M2.9M(46.87M)
Income Before Tax(43.27M)(25.81M)(23.28M)(18.58M)(68.65M)
Pre-Tax Margin-1110.6%-175.6%-260.3%-195.6%-471.6%
Income Tax Expense0541K(1.8M)0(5.11M)
Net Income(43.02M)(26.27M)(21.49M)(18.61M)(63.53M)
Net Margin-1104.2%-178.7%-240.2%-195.9%-436.5%
EPS (Basic)(0.26)(0.15)(0.12)(0.09)(0.28)
EPS (Diluted)(0.26)(0.15)(0.12)(0.09)(0.28)
Weighted Avg Shares164.5M169.79M172.66M200.19M230.12M
Weighted Avg Shares (Diluted)164.5M169.79M172.66M200.19M230.12M

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.